CureVac N.V. (5CV.DE)

2,1720 +0,0620 (+2,94%) Börsenschluss: 05:35PM CEST

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Alexander Zehnder M.B.A., M.D.	CEO, MD & Member of Management Board	978,33k	N/A	1970
Mr. Pierre Kemula B.Sc.	MD, CFO & Member of Management Board	654,17k	N/A	1975
Dr. Malte Greune Ph.D.	COO, Member of Management Board & MD	600,74k	N/A	1965
Dr. Myriam Mendila M.D.	Chief Development Officer, MD & Member of the Management Board	614,49k	N/A	1966
Dr. Ulrike Gnad-Vogt M.D., Ph.D.	Senior VP & Area Head of Oncology	284,14k	N/A	1973
Dr. Sarah Fakih	Vice President Corporate Communications & Investor Relations	N/A	N/A	N/A
Mr. Marco Rau L.L.M., Ph.D.	General Counsel	N/A	N/A	N/A
Mr. Thorsten Schuller	Head of Corporate Communications	N/A	N/A	N/A
Slavica Stevanovic-Heck	Head of Human Resources	N/A	N/A	N/A
Dr. Patrick Baumhof	Senior Vice President of Technology	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate Governance

CureVac N.V.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.